Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.88 -2.3%	$3.34	$1.07 ▼ $4.08	$1.04B	0.88	3.14 million shs	2.87 million shs
FENC Adherex Technologies	$8.71 -0.9%	$7.93	$3.96 ▼ $9.30	$242.60M	0.39	92,442 shs	56,480 shs
NRIX Nurix Therapeutics	$12.15 -4.3%	$11.32	$8.18 ▼ $29.56	$970.14M	2.15	846,237 shs	1.13 million shs
PRAX Praxis Precision Medicines	$51.89 -3.2%	$42.42	$26.70 ▼ $91.83	$1.09B	2.6	367,636 shs	396,506 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.27%	+4.58%	+8.99%	+104.21%	+196.18%
FENC Adherex Technologies	-0.91%	+0.11%	+9.84%	+70.78%	+33.18%
NRIX Nurix Therapeutics	-4.26%	-0.49%	+1.84%	+23.98%	-46.43%
PRAX Praxis Precision Medicines	-3.19%	+10.97%	+17.13%	+73.95%	+1.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.6558 of 5 stars	3.6	1.0	4.0	2.1	0.8	0.6
FENC Adherex Technologies	2.4576 of 5 stars	3.6	1.0	0.0	2.9	3.3	0.0
NRIX Nurix Therapeutics	2.4422 of 5 stars	4.4	1.0	0.0	3.0	0.8	0.0
PRAX Praxis Precision Medicines	2.2463 of 5 stars	4.4	1.0	0.0	1.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	73.97% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	49.25% Upside
NRIX Nurix Therapeutics	2.82	Moderate Buy	$29.31	141.26% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$94.11	81.37% Upside

Current Analyst Ratings Breakdown

Latest FENC, NRIX, PRAX, and AKBA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.36	N/A	N/A	($0.23) per share	-16.87
FENC Adherex Technologies	$30.91M	7.78	$0.03 per share	272.17	($0.21) per share	-41.48
NRIX Nurix Therapeutics	$54.55M	17.03	N/A	N/A	$5.85 per share	2.08
PRAX Praxis Precision Medicines	$8.55M	123.63	N/A	N/A	$23.90 per share	2.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	N/A
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)

Latest FENC, NRIX, PRAX, and AKBA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/12/2025	Q2 2025	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
FENC Adherex Technologies	N/A	5.13	4.97
NRIX Nurix Therapeutics	N/A	6.82	6.82
PRAX Praxis Precision Medicines	N/A	8.44	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
FENC Adherex Technologies	55.51%
NRIX Nurix Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
FENC Adherex Technologies	10.98%
NRIX Nurix Therapeutics	7.40%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.57 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable

FENC, NRIX, PRAX, and AKBA Headlines

Recent News About These Companies

Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 10.4% After Analyst Upgrade

July 11, 2025 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 10.4% on Analyst Upgrade

July 9, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $115.00 at Oppenheimer

July 8, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule ...

July 2, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by Brokerages

June 28, 2025 | marketbeat.com

Former head trader of Denver-based investing company pleads guilty to insider trading

June 9, 2025 | finance.yahoo.com

Weston man pleads guilty to insider trading offense that made him $220K

June 8, 2025 | stamfordadvocate.comS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2025 | globenewswire.com

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 7, 2025 | benzinga.com

Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation

May 7, 2025 | msn.com

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

May 5, 2025 | finance.yahoo.com

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

May 4, 2025 | finance.yahoo.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

Praxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | Benzinga

April 21, 2025 | benzinga.com

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

April 8, 2025 | globenewswire.com

Praxis Precision Medicines to Participate in Upcoming April Conferences

April 3, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 3, 2025 | globenewswire.com

Praxis Precision management to meet with Piper Sandler

March 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC, NRIX, PRAX, and AKBA Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.88 -0.09 (-2.27%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.10%)

As of 07/15/2025 07:14 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adherex Technologies NASDAQ:FENC

$8.71 -0.08 (-0.91%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$8.72 +0.01 (+0.11%)

As of 07/15/2025 04:24 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Nurix Therapeutics NASDAQ:NRIX

$12.15 -0.54 (-4.26%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$12.07 -0.08 (-0.63%)

As of 07:01 AM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$51.89 -1.71 (-3.19%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$51.94 +0.05 (+0.09%)

As of 07:00 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time